General Info
Host: | HEK293 cells |
Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: | 2019-nCoV Spike S1-C-hFc&His protein was developed from hek293 cells and has a target region of C-hFc&His. For use in research applications. |
Formulation: | Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. Contact us for customized product form or formulation. |
Immunoreactivity: | Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human ACE2 at 2 Mu g/mL (100 Mu L/well) can bind Recombinant SARS-CoV-2 Spike S1, the EC50 of SARS-COV-2 Spike S1 is 6.79 ng/mL.2. Immobilized Human ACE2 on COOH Chip can |
Information
Immunogen Region: | Val11-Arg682 |
Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6×His tag |
Description
Background | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6×His tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance